### SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity

- William S. Phipps, MD<sup>1,\*</sup>
- 4 Jeffrey A. SoRelle, MD<sup>1</sup>,\*
- 5 Quan-Zhen Li, MD, PhD<sup>2,3\*</sup>
- 6 Lenin Mahimainathan, PhD, MB(ASCP)<sup>1</sup>
- 7 Ellen Araj, MD<sup>1</sup>

1

2

16

24

27

35

38

40

- 8 John Markantonis, DO<sup>1</sup>
- 9 Chantale Lacelle, PhD<sup>1</sup>
- 10 Jvoti Balani, MD<sup>1</sup>
- 11 Hiren Parikh, MT(ASCP)<sup>1</sup>
- 12 E. Blair Solow, MD, MSCS<sup>2</sup>
- 13 David R. Karp, MD, PhD<sup>2</sup>
- 14 Ravi Sarode, MD <sup>1,4</sup>
- 15 Alagarraju Muthukumar<sup>1,</sup> PhD, DABCC #
- <sup>1</sup> Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
- <sup>2</sup> Department of Internal Medicine (Rheumatic Diseases), University of Texas Southwestern
- 19 Medical Center, Dallas, Texas
- <sup>3</sup> Department of Immunology, Microarray Core Facility, University of Texas Southwestern
- 21 Medical Center, Dallas, Texas
- <sup>4</sup> Department of Internal Medicine (Hematology/Oncology), University of Texas Southwestern
- 23 Medical Center, Dallas, Texas
- 25 \*These authors contributed equally to this work. Author order was determined by chronological
- order of becoming involved with the project.
- 28 #Send correspondence to:
- 29 Alagarraju Muthukumar, PhD
- 30 Department of Pathology
- 31 5323 Harry Hines Blvd
- 32 Dallas, TX 75390
- 33 Tel:214-645-5103
- 34 Email: Alagarraju.Muthukumar@UTSouthwestern.edu
- 36 Running Title: SARS-CoV-2 Antibody responses and COVID-19 severity
- 37 Key words: COVID-19, Coronavirus Disease 2019, SARS-CoV-2, Clinical Validation, EUA
- 39 Commercial Interest Disclosure:
- The following authors have no interests to disclose: WP, JS, QL, LM, EA, JM, CL, JB, HP, EBS,
- 42 DK, RS, AM
- The following authors have these interests to disclose: None

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

61

63

64

65

population.

**ABSTRACT** 

**Background:** Initial reports indicate adequate performance of some serological-based SARS-CoV-2 assays. However, additional studies are required to facilitate interpretation of results, including how antibody levels impact immunity and disease course. **Methods:** In this study, a total of 968 subjects were tested for IgG antibodies reactive to SARS-CoV-2. We confirmed analytic specificity using 656 plasma samples from healthy donors, 49 sera from patients with rheumatic disease, and 90 specimens from individuals positive for PCRbased respiratory viral panel. One-hundred seventy-three cases of confirmed or suspected SARS-CoV-2 were tested for IgG. A subgroup of 37 SARS-CoV-2 PCR-positive cases was tested for nucleocapsid-specific IgM antibody using an in-house developed microarray method. Antibody levels were compared between disease severity groups. **Results:** All specificity specimens were negative for SARS-CoV-2 IgG antibodies (0/656, 0%). Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid factor, or cases with previous diagnosis of viral infection including human coronavirus. Positive agreement of IgG with PCR was 83% of samples confirmed to be more than 14 days from symptom onset, with less than 100% sensitivity attributable to a case with severe 60 immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3 days from symptom onset. No association was observed between mild and severe disease course 62 with respect to IgG and IgM levels. Conclusions: The studied SARS-CoV-2 IgG assay had 100% specificity and no adverse crossreactivity. Index values of IgG and IgM antibodies did not predict disease severity in our patient

#### INTRODUCTION

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

As the COVID-19 global pandemic (1) continues, a major priority is the application of serological testing to determine the scale and rate of exposures. The COVID-19 pathogen, SARS-CoV-2 (2), is an enveloped, positive-sense, single-stranded RNA Betacoronavirus with a ~30 kilobase genome. The molecular detection of SARS-CoV-2 is based on targeting the viral genome (e.g., Orf1a/b, E, S, N genes) by polymerase chain reaction (PCR) (3–7), and is currently the gold standard to diagnose acute infection (3). Cellular and humoral immunity resolve the infection, which can be detected by the formation of antibodies specific for the virus. Various serological assays have recently acquired FDA's emergency use authority (EUA) for SARS-CoV-2 antibody testing in COVID-19 patients, but the interpretation of antibody data and their clinical significance remains challenging. Understanding the time course of antibody response and potential reasons for apparent failure of seroconversion are essential. Further, before assessing whether specific antibodies ameliorate SARS-CoV-2 infection or prevent reinfection, confidence in the analytical specificity of the test is required. Antibody assays are frequently susceptible to non-specific reactivity leading to false positives. This can have dramatic effects when the incidence of exposure is low. Thus, a high positive predictive value gained from minimal cross reactivity towards other pathogen or autoimmune-associated antibodies is critical. Long, et al. have described a variable antiviral IgM and IgG immune response to SARS-CoV-2 infection in a Chinese population (8), in which seroconversion in a group of 285 patients from 3 hospitals, showed IgG positivity for all cases beyond 17-19 days. Bryan, et al. demonstrated timing of seroconversion for an Idaho population (9). Additional studies are lacking for the U.S.

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

population. The goals of this study were to ascertain key performance metrics of analytical specificity and cross reactivity for a SARS-CoV-2 IgG serological assay, perform a detailed cross-sectional and serial assessment of IgG and IgM antibody responses in suspected COVID-19 patients, and determine their relation to disease severity. MATERIALS AND METHODS **Patient samples.** This study was approved by the UT Southwestern Institutional Review Board. A total of 968 individuals (996 total specimens) were included in this study, including 656 healthy controls, 29 patients with systemic lupus erythematosus, 20 with rheumatoid arthritis, 90 with previous positive respiratory viral PCR panel, and 173 confirmed or suspected cases of COVID-19 (**Fig. 1**). SARS-CoV-2 IgG Testing. SARS-CoV-2 IgG (Abbott 06R86) testing was performed on the Abbott ARCHITECT i2000SR in accordance with manufacturer's specifications. The test is a chemiluminescent microparticle immunoassay (CMIA) for qualitative detection of IgG antibodies against SARS-CoV-2 nucleocapsid protein (NCP) in human serum and plasma. Strength of response in relative light units (RLU) reflects quantity of IgG present, and is compared to a calibrator to determine the calculated Index (Specimen/Calibrator, S/C) for a sample (with positive at 1.4 or greater). SARS-CoV-2 IgM testing. IgM antibody reactivity against SARS-CoV-2 NCP was measured using a laboratory developed protein microarray as described previously (10). Briefly, NCP expressed in baculovirus insect cells (Sino Biological) and in E. Coli (Creative Diagnostics) along with control proteins (human IgM and anti-human IgM) were printed onto nitrocellulose

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

membrane coated slides (Grace Bio) in sextuple using a Nanoplotter NP2.1 microarray Inkjet printer (Gesim, Germany). Patient serum samples were diluted 1:100 and incubated with the antigens on the array and the IgM antibody specificities detected with cy5-conjugated antihuman IgM (1:1000, Jackson ImmunoResearch). The array was scanned using Genepix 4400A scanner (Molecular Device) at wavelength 635 nm. The resulting images were analyzed using Genepix Pro 7.0 software (Molecular Devices). The median of the signal intensity for each spot was calculated and the local background around the spot subtracted, and data obtained from sextuple spots were averaged. The background subtracted signal intensity was normalized to the average intensity of the total human IgM (internal positive control) to generate normalized signal intensity (NSI). Samples with NSI ≥25 were considered positive for IgM. The NSI of NCP IgM was used to generate heat maps using Cluster and Treeview software (http://bonsai.hgc.jp/~mdehoon/software/cluster/index.html). Analytical specificity. Specificity was evaluated using 240 banked plasma samples collected prior to the COVID-19 pandemic (blood donors September through November 2019), and an additional 416 healthy donors without recent illness collected from March to April, 2020. Cross-reactivity studies. Cross reactivity specimens were collected by cross referencing banked serum in the HLA lab (January 1, 2015- September 30, 2019) with patients who had previously tested positive for cytomegalovirus (CMV IgG), influenza A/B, RSV, or an endemic Coronavirus (NL63, 229E, OC43 or HKU1) by viral molecular tests. As the patients may have been immunosuppressed, we included only those specimens having normal or high levels of total IgG (measured alongside SARS-CoV-2) with no infusion of intravenous immunoglobulin in the preceding 3 months. Interfering substance specimens came from a collection of residual serum from a study of systemic lupus erythematosus patients that were positive for ANA and other

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

autoantibodies (n=29 collected 2004-2007). Patient samples strongly positive for rheumatoid factor (n=20 collected 2011-2014) were also evaluated. Agreement with PCR-based testing. Agreement with PCR-based molecular testing was determined using 173 plasma samples collected (147 lithium heparin, 13 EDTA, 12 sodium citrate, and 1 sodium fluoride anticoagulants) from suspected COVID-19 cases with prior or same-day PCR-based nasopharyngeal swab testing on the m2000 Abbott RealTime SARS Cov-2 assay or the Abbott ID NOW<sup>TM</sup> COVID-19 assay. Patient charts were reviewed to determine time between symptom onset (fever, respiratory symptoms, or gastrointestinal complaints) and severity of condition (whether or not intensive care was required). A subgroup of 37 PCRpositive cases (17 IgG positive, 20 IgG negative) were additionally evaluated for SARS-CoV-2 IgM. Serial Patient Monitoring. For 15 PCR-positive cases, two to six serial measurements were performed using available residual plasma samples. IgG levels and seroconversion based on calculated Index (S/C) were tracked over time. Statistics. The calculated Index (Specimen/Calibrator, S/C, IgG level) was provided by the instrument. When multiple values of IgG S/C were compared, a mean and standard deviation were calculated. Student's t-test was used to compare two groups of non-parametrically distributed data and p-value < 0.05 was considered significant. **RESULTS** Analytical Specificity. The SARS-CoV-2 IgG assay was calibrated followed by an imprecision study performed over a period of 5 consecutive days and was found to be acceptable. Analytical

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

specificity of the assay was evaluated with samples from healthy blood donors and none of these samples (0/656) were positive for virus-specific IgG (**Table 1**) and the mean index value was 0.04, well below the cut-off of 1.4 for a positive index value. *Cross-reactivity studies.* To determine whether antibodies formed in response to viral respiratory infections may cross-react with the SARS-CoV-2 antigen (NCP) on the assay's paramagnetic beads, we included samples of patients who had tested positive on a molecular based respiratory viral panel test (Table 1). We excluded any patients treated with intravenous immunoglobulin in the last 3 months. As some patients were post-transplant and on immunosuppression medications, we quantitated total IgG and excluded any samples with hypogammaglobulinemia (low IgG) to reduce false negative results. We tested 23 CMV IgG positive samples and none were COVID-19 IgG positive (0/23, 0%). No cases associated with prior Flu A+ (n=8), Flu B+ (n=7), RSV+ (n=6), or all 4 types of human coronavirus (n=47) demonstrated cross-reactivity (0/90, 0%). Likewise, we tested 29 samples from lupus patients that were positive for multiple autoantibodies (100% ANA, 62% anti-dsDNA, 75% anti-U1RNP, 55% anti-Sm, 34% anti-Ro52, and 24% anti-La) and an additional 20 samples from rheumatoid arthritis patients positive for rheumatoid factor (85% were also anti-CCP positive). None of these sera with clinically significant levels of autoantibodies produced a positive antiviral IgG test result (0/49, 0%) (Table 2). Highest mean of S/C ratio observed was 0.05 for human coronaviruses and 0.08 for rheumatic diseases. Cross-Sectional data for SARS-CoV-2 IgG and IgM. Of 173 suspected COVID-19 cases, 76 were confirmed positive by PCR methods. Overall, 29 of 76 (38%) tested positive for SARS-

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

CoV-2 IgG. The time course of symptom onset revealed increasing IgG positivity rates (**Table 3**) from <3 days (1/15, 7%), to 3-7 days (8/27, 30%), 5-15 (5/15, 33%), and being the highest after 14 days (5/6, 83%). IgG positivity was high (10/13, 77%) for patients with indeterminate time from symptom onset. IgM testing (Fig. 2) performed on 37 PCR positive specimens showed positivity in 9 of 17 (53%) IgG positive cases and, interestingly, in 7 of 20 (35%) IgG negative samples. IgM positivity occurred at larger proportion for <3 days (3/6, 50%) compared to IgG, but at similar rates overall at days 3-7 (4/11, 36%), days 8-13 (4/11, 36%), and after 2 weeks (4/5, 80%). IgM positivity was low (1/4, 25%) for patients with indeterminate time from symptom onset. SARS-CoV-2 IgG antibody results agreed with the PCR negative samples for 96 of 97 (99%) of cases, including 55 instances of patients with new or acute-on-chronic symptoms suspicious for COVID-19 and with known time of onset. Disease severity and IgG and IgM value. We hypothesized that a more severe disease course was related to an increased immune response, which may result in a higher level of SARS-CoV-2 IgG antibody reactivity. Cytokine storm has been implicated as a potential life-threatening event in SARS-CoV-2 infection, and this would activate many aspects of the immune system including the humoral antibody response. We compared IgG levels from all SARS-CoV-2 PCRpositive patients who had a mild/ moderate disease course to those who had severe disease (admitted to the ICU), and there was no difference in IgG antibody levels between the two groups (Fig 3A). Next, we assessed the impact of timing of collection on the antibody response by comparing the number of days since symptom onset between mild/ moderate and severe disease status (Fig.

**3B**). Severely affected patients had higher IgG antibody levels measured at a later time compared to mild cases (p<0.05). Similarly, higher IgM levels were observed in severely affected patients (**Fig. 3C, D**). It is possible that the course of IgG levels was qualitatively different in severe patients, so data from serially collected IgG samples was plotted against day of symptom onset (Fig. 4). Severely affected patients were tracked longer, because they were hospitalized longer, but a similar early increase in antibody titers was observed in mild/moderately affected patients when compared to severely affected patients. Interestingly, one patient was seronegative even on day 28, but this was attributed to immunosuppression to prevent cardiac transplant rejection. Serial Patient Monitoring and Seroconversion. Thirty-eight samples were available from 13 patients with known date of symptom onset (Fig. 3C) and 4 samples from 2 patients with indeterminate date of symptom onset. Within this group, 77% (10/13) became IgG positive, including specifically 0% (0/8) for less than 3 days post symptom onset, 33% (3/9) at 3-7 days post-symptom onset, 86% (6/7) at 8-13 days post-symptom onset, and 91% (10/11) at more than 14 days (**Figure 4**). For those where seroconversion was not observed, samples were only available for less than 7 days from symptom onset for 2 cases or patient was subject to significant immunosuppression. For the two cases with indeterminate date of symptom onset, one demonstrated seroconversion between samples 11 days apart. The second case did not demonstrate seroconversion over 9 days.

#### **DISCUSSION**

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Here we confirmed the high specificity reported by the manufacturer for a SARS-CoV-2 IgG serological assay, using comparatively larger groups for certain rheumatological conditions and infections. Notably, CMV IgG did not cause assay interference despite potential false positivity

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

reported by the manufacturer. Rheumatoid factor is an anti-human antibody (IgM or IgG) that, if complexed with other human immunoglobulins, could falsely increase positivity of an assay. However, we observed no interference by rheumatoid factor in 20 samples. Testing 47 samples with prior endemic coronavirus infection yielded no false positives. Negative agreement between IgG and PCR indicated only one case testing IgG positive despite negative PCR testing. This initial PCR result was later determined to be a false negative based on evaluation using an alternative molecular platform. Positive agreement with PCR was lower in the early stages of infection, increasing with time from symptom onset, yet not as quickly compared to the manufacturer's report. Overall, our results largely corroborate and add to the findings by Bryan, et al. (9) who evaluating the same platform. The study showed high specificity in testing 1020 specimens submitted for HSV Western blot serology from before the COVID-19 pandemic. As such, specificity and cross reactivity were not specifically addressed in the setting of underlying rheumatologic disease or previous endemic coronavirus. A possible difference between our findings was sensitivity after 14 days of symptoms. In our study, a single negative case attributed to a patient with marked immunosuppression resulted in reduced sensitivity beyond 14 days. An unknown factor in similar studies are the number of cases included with severe underlying immunosuppression. For instance, a recent publication by Long, et al. also indicated 100% IgG positivity at 17-19 days. This latter study utilized a different assay and focused on a population in China, and was thus not as comparable. However, the same question persists regarding the makeup of comorbidities in the test population and highlights that discrepancies may arise in antibody response when comparing serology in unequal groups. Nonetheless, within our serial testing group, given the higher number of cases beyond 14 days, we did encounter sensitivity of

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

91% (10/11), which was closer to the findings of Bryan and Long. As with Bryan, et al., we have noticed alternative cutoff values for IgG level could be utilized with potentially beneficial diagnostic effects. As an example, lowering the cutoff by half (to 0.7) would capture an additional four cases with mid-range days from symptom onset (5 to 11) without any loss in specificity based the PCR result. Long, et al. had reported a counter-intuitive peak of IgM positivity (20-22 days) later than for IgG positivity (17-19 days). IgM responses usually peak within the first week after infection and before IgG class switching. When early in infection, IgG may not yet be positive. When we tested samples for IgM reactivity, seven IgG negative cases were positive for IgM. These samples were positive for IgM earlier than IgG, with onset ranging from 0 to 11 days from symptom onset. This increased the sensitivity by 35% within the IgG negative samples tested (7/20) and improved diagnostic utility by 9% overall (7/76). As described, we segregated our IgG and IgM results based on severity (ICU care versus no ICU care). Long, et al. indicated that a severe disease course resulted in a high IgG level during the second week of disease that becomes indistinguishable from milder cases after 14 days (9). We did not observe such a difference using a different CMIA method. This could be due to fewer patient samples, but the significance of their finding was very strong, which indicates it should have replicated were it a real phenomenon. IgM levels in our study showed no significant difference when analyzed by disease severity. Thus, antibody levels themselves do not appear to reflect disease severity. A major hurdle to validation was access to patients after a sufficient time period of infection because most patients presented before 14 days from symptom onset. Limited resources and self-

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

quarantine measures have impaired repeated testing for serial testing at a later date. Consequently, less data on mild and moderate patients existed compared to patients admitted to the ICU. We do however have the advantage of reviewing medical charts to find examples of false negative by PCR and false negative by serology. These examples indicate that molecular and serologic testing have complementary roles in tracking exposure to SARS-CoV-2. Our data does not provide information on how long IgG stays positive in the long term or whether it specifically confers immunity. **CONCLUSIONS** As communities continue to grapple with the COVID-19 pandemic, reliable measures of previous exposure and immunity are essential. Several platforms are now coming into broader clinical use, providing a window into the SARS-CoV-2 antibody response. Widespread efforts to track SARS-CoV-2 patients for antibody development will clarify expectations for when testing should return positive, situations in which seroconversion may fail, and what the antibody response can tell us in patients with active infections. ACKNOWLEDGMENTS We would like to thank Clements University Hospital Core lab staff, especially Brittany Diaz, Sylvnn Garza and Charles Alexis for serology testing and archiving of all the samples related to this study. We also acknowledge Carter Blood Care (Bedford, TX) for their archived patient samples for specificity studies and the Human Leukocyte Antigen lab at UT Southwestern for their help in retrieving banked serum samples for cross-reactivity studies, as well as Dr. Ashley Young for aid in chart review.

## **RFERENCES**

287

288 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-289 L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, 290 Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-291 F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable 292 bat origin. Nature 579:270–273. 293 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. 2. 294 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 295 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544. 296 3. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel For 297 Emergency Use Only Instructions for Use. Centers for Disease Control and Prevention, 298 Atlanta, GA 299 Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink 4. 300 S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink 301 S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, 302 Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-303 nCoV) by real-time RT-PCR. Eurosurveillance 25. 5. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV 304 305 in humans. World Health Organization. https://www.who.int/emergencies/diseases/novel-306 coronavirus-2019/technical-guidance/laboratory-guidance. Accessed March 31, 2020.

307 6. Chan JF-W, Yip CC-Y, To KK-W, Tang TH-C, Wong SC-Y, Leung K-H, Fung AY-F, 308 Ng AC-K, Zou Z, Tsoi H-W, Choi GK-Y, Tam AR, Cheng VC-C, Chan K-H, Tsang OT-309 Y, Yuen K-Y. 2020. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly 310 Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR 311 Assay Validated In Vitro and with Clinical Specimens. J Clin Microbiol 58. 312 7. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, 313 Yang P, Wang Q, Peiris M, Poon LLM. 2020. Molecular Diagnosis of a Novel 314 Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem 66:549–555. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai 315 8. 316 X-F, Wang D-Q, Hu Y, Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L, 317 Tian W-G, Hu L, Zhang X-X, Xiang J-L, Du H-X, Liu H-W, Lang C-H, Luo X-H, Wu S-318 B, Cui X-P, Zhou Z, Zhu M-M, Wang J, Xue C-J, Li X-F, Wang L, Li Z-J, Wang K, Niu 319 C-C, Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J, Zhang D-C, Zhang F, Liu P, Yuan J, 320 Li Q, Hu J-L, Chen J, Huang A-L. 2020. Antibody responses to SARS-CoV-2 in patients 321 with COVID-19. Nat Med. 322 9. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, 323 Mathias PC, Greninger AL. 2020. Performance Characteristics of the Abbott Architect 324 SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol. 325 10. Zhen QL, Xie C, Wu T, Mackay M, Aranow C, Putterman C, Mohan C. 2005. 326 Identification of autoantibody clusters that best predict lupus disease activity using 327 glomerular proteome arrays. J Clin Invest 115:3428–3439.

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

FIGURE LEGENDS Figure 1. Study Cases. Nine-hundred and sixty eight (968) unique individuals provided samples for SARS-CoV-2 IgG testing, including 15 with serial samples available. IgM testing (not shown) was performed on a group of 37 specimens (17 IgG positive, 20 IgG negative). Figure 2. IgM Microarray Analysis. Array images of IgM positive and negative samples are shown (A) as well as heatmap of IgM anti-SARS-CoV-2 NCP are shown for IgG positive and negative cases of confirmed COVID-19. Figure 3. Antibody levels by disease severity for PCR+ subjects. (A) SARS-CoV-2 specific IgG antibody results which were positive or negative were divided by disease severity and (B) plotted against number of days from symptom onset. (C) SARS-CoV-2 nucleocapsid specific IgM antibody results were divided by IgG positivity to demonstrate when a sample was IgM+, but IgG-. (D) IgM antibody levels were plotted against number of days from symptom onset. Middle line is the mean bars represent standard deviation. Black dots are mild/moderate cases, while red dots represent severe cases. The red dash line in (B) represents the negative cut off level. Figure 4. Serial IgG measurements. For patients with multiple samples taken, the IgG level was plotted against time from symptom onset. Black dots represent the IgG level at a specific time. Samples from the same patient are connected by either red (severe cases) or black lines (mild/moderate cases). The dotted line indicates the threshold for a sample being positive.

# **TABLES**

351

352

353

**Table 1. SARS-CoV-2 IgG Results in Healthy Donors** and Cases of Previous Respiratory Viral Infection

Sample Type	IgG, AU/mL
Blood Donors	
Mean±SD	$0.039 \pm 0.065$
Positive of n tests (%)	0/656 (0%)
CMV IgG+	
Mean±SD	$0.07 \pm 0.067$
n of Positive tests (%)	0/23 (0%)
Flu A+	
Mean±SD	$0.13\pm0.19$
n of Positive tests (%)	0/8 (0%)
Flu B+	
Mean±SD	$0.11\pm0.17$
n of Positive tests (%)	0/7 (0%)
RSV+	
Mean±SD	$0.035 \pm 0.029$
n of Positive tests (%)	0/6 (0%)
Coronavirus +	
Mean±SD	$0.050\pm0.079$
n of Positive tests (%)	0/47 (0%)

**Table 2. Autoantibody Interference** 

IgG Positivity Rate (%)			
Systemic lupus erythematosus (29 Patients) <sup>a</sup>			
0/29 (0%)			
0/17 (0%)			
0/21 (0%)			
0/15 (0%)			
0/10 (0%)			
0/7 (0%)			
Rheumatoid arthritis (20 Patients) b			
0/20 (0%)			

<sup>&</sup>lt;sup>a</sup> Cases (29 total) were positive for 1 or more of the autoantibodies listed.

Anti-CCP

354

355


0/17 (0%)

<sup>&</sup>lt;sup>b</sup> All cases were RF positive, with 17/20 (85%) also anti-CCP positive.


Table 3. SARS-CoV-2 IgG Positive Agreement by Days Post-Symptom Onset

Time from symptom onset *	IgG Positivity Rate (%)	IgM Positivity Rate (%)
<3 days	1/15 (7%)	3/6 (50%)
3-7 days	8/27 (30%)	4/11 (36%)
8-13 days	5/15 (33%)	4/11(36%)
>14 days	5/6 (83%)	4/5 (80%)
Indeterminate	10/13 (77%)	1/4 (25%)
Total	29/76 (38%)	16/37 (43%)

<sup>\*</sup> For RT-PCR confirmed SARS-CoV-2 cases



**Figure 1. Study Cases.** Nine-hundred and sixty eight (968) unique individuals provided samples for SARS-CoV-2 IgG testing, including 15 with serial samples available. IgM testing (not shown) was performed on a group of 37 specimens (17 IgG positive, 20 IgG negative).



**Figure 2. IgM Microarray Analysis.** Array images of IgM positive and negative samples are shown **(A)** as well as heatmap of IgM anti-SARS-CoV-2 NCP are shown for IgG positive and negative cases of confirmed COVID-19 **(B)**.





Figure 3. Antibody levels by disease severity for PCR+ subjects. (A) SARS-CoV-2 specific IgG antibody results which were positive or negative were divided by disease severity and (B) plotted against number of days from symptom onset. (C) SARS-CoV-2 nucleocapsid specific IgM antibody results were divided by IgG positivity to demonstrate when a sample was IgM+, but IgG-. (D) IgM antibody levels were plotted against number of days from symptom onset. Middle line is the mean bars represent standard deviation. Black dots are mild/moderate cases, while red dots represent severe cases. The red dash line in (B) represents the negative cut off level.



**Figure 4. Serial IgG measurements.** For patients with multiple samples taken, the IgG level was plotted against time from symptom onset. Black dots represent the IgG level at a specific time. Samples from the same patient are connected by either red (severe cases) or black lines (mild/ moderate cases). The dotted line indicates the threshold for a sample being positive.